Académique Documents
Professionnel Documents
Culture Documents
37 weeks), and maternal smoking status (smoker, non-
smoker), using design variables.
We used logistic regression analyses to estimate the
association between use of amoxicillin and low birth
weight (
2500 g), preterm delivery (
<
37 weeks), con-
genital malformations, and perinatal death. The analyses
were adjusted for maternal age and smoking, and these
variables were coded as described above. The analysis of
low birth weight was restricted to full-term deliveries
(
37 weeks), and only prescriptions for amoxicillin
redeemed in the rst trimester were included in the
analysis of congenital malformations.
Casecontrol analysis
The risk of spontaneous abortion
in women exposed to amoxicillin during pregnancy rel-
ative to controls was estimated using a logistic regression
model adjusted for maternal age divided into three
categories (
<
25, 2530, and
>
30 years) using design
variables.
Results
Cohort analysis
We identied 401 primiparous women who redeemed a
prescription for amoxicillin during pregnancy, and 147
of them redeemed their prescription during the rst
trimester. The control group consisted of 10 237 primi-
parous women who did not redeem any prescriptions
from 3 months before conception until delivery. In the
group of women exposed to amoxicillin at any time
during pregnancy, average birth weight was 3498 g, 5.0%
had a preterm delivery, and 4.0% gave birth to a child
with a congenital malformation. The corresponding
numbers in the control group were 3429 g, 6.3%, and
4.1% (Table 1). There were no cases of perinatal death in
the exposed group, so this outcome was not examined
in logistic regression analysis.
According to the multiple regression analysis, adjusted
mean birth weight of children born to mothers in the
exposed group was 57 g [95% condence interval (CI)
9, 105] higher than that of children born to controls.
In adjusted logistic regression analyses, risk of low
birth weight [odds ratio (OR) 0.63, 95% CI 0.26, 1.53]
and preterm delivery (OR 0.77; 95% CI 0.49, 1.21) was
nonsignicantly reduced, while risk of congenital mal-
formations (OR 1.16; 95% CI 0.54, 2.50) was close to
unity among children born to mothers in the exposed
group compared with those born to controls (Table 2).
Table 1
Characteristics of the study cohort.
Exposed to amoxicillin
in the rst trimester
Exposed to amoxicillin
during pregnancy Controls
Number of women 147 401 10 237
Number of prescriptions 150 445
Mean age (range) 27.4 (1842) 27.0 (1642) 26.8 (1345)
Proportion of smokers (%) 35.4 33.4 25.9
Gestational age (weeks)
37 139 381 9 588
3436 8 18 450
2833 0 2 199
Mean birth weight (range) 3518 (22704665) 3498 (18154675) 3 429 (5166230)
Number of low birth weight* (%) 2 (1.4) 5 (1.3) 183 (1.9)
Number of preterm deliveries (%) 9 (6.1) 20 (5.0) 649 (6.3)
Number of malformations (%) 7 (4.8) 16 (4.0) 416 (4.1)
Number of perinatal deaths (%) 0 (0) 0 (0) 60 (0.6)
*Restricted to full term deliveries (
37 weeks).
Maternal use of amoxicillin and pregnancy outcome
2003 Blackwell Science Ltd
Br J Clin Pharmacol
,
55
, 216221
219
Casecontrol analysis
In the analysis of spontaneous abortion, we found that
52 (1.2%) of the women in the case group redeemed a
prescription for amoxicillin compared with 437 (1.3%)
of the controls. After adjustment for maternal age, the
OR for spontaneous abortion was 0.89 (95% CI 0.66,
1.18) (Table 2).
Discussion
In this study, which we believe is the rst follow-up
study of the safety of amoxicillin in pregnancy, we found
that women who redeemed a prescription for amoxicillin
during pregnancy tended to give birth to babies with
higher birth weight, but were not at increased risk for
adverse pregnancy outcomes such as preterm delivery,
congenital malformations, or spontaneous abortion.
Use of the prescription database, which has no more
than 0.2% coding errors [12], ensured virtually complete
registration of redeemed prescriptions. Furthermore,
since patients are required to pay part of the cost of
prescribed amoxicillin, the use of prescriptions that were
actually redeemed is likely to have reduced misclassi-
cation due to noncompliance. However, it is still pos-
sible that not all amoxicillin was actually taken [13].
In-hospital use of amoxicillin is an additional source of
misclassication as it is not recorded in the prescription
database. Any misclassication of amoxicillin use will lead
to a conservative bias.
We may have overestimated the effect of amoxicillin
on pregnancy outcome, because women in the amoxicil-
lin group could have redeemed prescriptions for other
drugs than amoxicillin during pregnancy, whereas the
controls did not redeem any prescriptions during
pregnancy.
Registration of births and stillbirths was of high qual-
ity. The predictive value and completeness of diagnoses
of congenital malformations in the County Hospital Dis-
charge Registry have been estimated at 90% (unpublished
data), but we do not believe that either predictive value
or completeness could be associated with use of amox-
icillin. However, we were not able to identify malformed
fetuses detected at prenatal examinations and conse-
quently aborted, and we do not know whether these
malformations were associated with exposure to amox-
icillin. Lack of completeness and of data from prenatal
examinations may explain the slightly lower occurrence
of congenital malformations in this study (4.1% among
controls) compared with the 4.8% (after subtraction of
congenital dislocation of the hip and undescended testes)
reported in a Hungarian study [14].
If amoxicillin does cause congenital malformations, it
would probably cause only a few specic malformations,
and it would take a large number of these specic mal-
formations to produce a statistically signicant increase
in congenital malformations overall [15]. We had the
power to detect only a 2.5-fold increased risk of con-
genital malformations overall.
With respect to spontaneous abortion, we were able
to identify only spontaneous abortions which resulted in
hospitalization. Thus, we cannot report on the association
between amoxicillin exposure and early spontaneous
abortion that did not require hospitalization.
We assumed that all spontaneous abortions occurred at
12 weeks of gestation, because we did not know the
exact gestational age at the time of the abortion. If it
occurred before week 12 of gestation, we could have
included prescriptions redeemed before conception.
Conversely, if the spontaneous abortion occurred after
week 12 of gestation, we may have missed prescriptions
redeemed early in pregnancy. Thus, we may have mis-
classied amoxicillin exposure, resulting in a conservative
bias.
Smoking is a risk factor of spontaneous abortion [16],
but we were unable to adjust for smoking in our case
control analysis, because we did not know the smoking
status of women with a spontaneous abortion. However,
Table 2
Probability of pregnancy outcomes in the amoxicillin group relative to controls.
Exposure to amoxicillin
Crude odds ratio 95% CI Adjusted odds ratio 95% CI
Cohort analysis
Low birth weight* 0.68 0.281.67 0.63
0.261.53
Preterm delivery 0.78 0.491.22 0.77
0.491.21
Congenital malformations 1.18 0.552.54 1.16
0.542.50
Casecontrol analysis
Spontaneous abortion 0.92 0.691.23 0.89
0.661.18
*Restricted to full-term deliveries (
37 weeks).
Adjusted for smoking and maternal age.
Adjusted for maternal age.
P. Jepsen
et al
.
220
2003 Blackwell Science Ltd
Br J Clin Pharmacol
,
55
, 216221
we did nd a higher proportion of smokers among
women exposed to amoxicillin in our cohort analysis
(33.4%
vs
25.9% among controls), suggesting that smok-
ing is unlikely to explain the slightly protective effect of
amoxicillin on spontaneous abortion.
Our nding of a higher birth weight among children
born to mothers exposed to amoxicillin is consistent with
ndings from other studies of antibiotics in pregnancy [3,
4], but the opposite has also been reported [5]. However,
we believe that the magnitude of the weight difference
found in this study (57 g) was too small to have any
prognostic impact. One explanation for our nding
could be that antibiotic treatment during pregnancy pre-
vents infections that would otherwise cause lower birth
weight. However, confounding by socio-economic sta-
tus, whereby women of low socio-economic status,
which may be associated with low birth weight [17], did
not receive appropriate antibiotic treatment, cannot be
ruled out.
A previous randomized trial, including 252 pregnant
women with probable gonorrhoea, found similar risk of
congenital malformations among those who were treated
with amoxicillin and in those treated with ceftriaxone or
spectinomycin [8]. To our knowledge, there are no stud-
ies to date of the association between amoxicillin and
either low birth weight, perinatal death, or spontaneous
abortion. Augmentin is a combination of amoxicillin and
clavulanic acid, and a Hungarian casecontrol study
including 52 (0.75%) augmentin-exposed women among
6935 who had offspring with congenital malformations
reported a nonsignicantly increased odds ratio for con-
genital malformations overall of 1.4 compared with
10 238 controls [7]. The risks of cleft lip or palate (OR
2.1; 95% CI 0.6, 7.1), poly/syndactyly (OR 2.5; 95% CI
0.4, 16.3), cardiovascular malformations (OR 2.6; 95%
CI 1.1, 6.0), malformations of diaphragm (OR 7.0; 95%
CI 0.4, 135.5), and hypospadias (OR 4.3; 95% CI 1.2,
15.4) were increased after exposure to augmentin at any
time during pregnancy, and not only during the critical
period for congenital malformations. As the data on aug-
mentin exposure were based on questionnaires, recall bias
might have contributed to the ndings [18]. Pivampicil-
lin and ampicillin are closely related to amoxicillin, and
another Hungarian study of ampicillin use in 61 016
pregnant women, based on the same casecontrol dataset,
did not report increased risk of serious congenital mal-
formations [6]. Similarly, a Danish study of 199 women
who received pivampicillin in the rst trimester did not
nd any increased risk of malformations, preterm deliv-
ery, or low birth weight [4].
In conclusion, amoxicillin use during pregnancy does
not appear to increase the risk of adverse pregnancy
outcome, but even this large study cannot rule out an
effect.
This study has received nancial support from the Western Danish
Research Forum for Health Sciences.
References
1 Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg
Olsen J, Srensen HT. Drug use in rst pregnancy and
lactation: a population-based survey among Danish women.
The EUROMAP Group.
Eur J Clin Pharmacol
1999;
55
: 139
144.
2 The Danish Medicines Agency.
Medicinal Products Statistics
19941998.
Albertslund: Schult Information, 1999.
3 Larsen H, Nielsen GL, Mller M, Ebbesen F, Schnheyder
HC, Srensen HT. Birth outcome and risk of neonatal
hypoglycaemia following
in utero
exposure to pivmecillinam:
a population-based cohort study with 414 exposed
pregnancies.
Scand J Infect Dis
2001;
33
: 439444.
4 Larsen H, Nielsen GL, Srensen HT, Mller M, Olsen J,
Schnheyder HC. A follow-up study of birth outcome in
users of pivampicillin during pregnancy.
Acta Obstet Gynecol
Scand
2000;
79
: 379383.
5 Czeizel AE, Rockenbauer M, Olsen J. Use of antibiotics
during pregnancy.
Eur J Obstet Gynecol Reprod Biol
1998;
81
:
18.
6 Czeizel AE, Rockenbauer M, Srensen HT, Olsen J. A
population-based casecontrol teratologic study of ampicillin
treatment during pregnancy.
Am J Obstet Gynecol
2001;
185
:
140147.
7 Czeizel AE, Rockenbauer M, Srensen HT, Olsen J.
Augmentin treatment during pregnancy and the prevalence
of congenital abnormalities: a population-based casecontrol
teratologic study.
Eur J Obstet Gynecol Reprod Biol
2001;
97
:
188192.
8 Cavenee MR, Farris JR, Spalding TR, Barnes DL, Castaneda
YS, Wendel GD Jr. Treatment of gonorrhea in pregnancy.
Obstet Gynecol
1993;
81
: 3338.
9 Friedman JM, Polifka JE.
The Effects of Drugs on the Fetus and
Nursing Infant
, 1st edn. Baltimore and London: The Johns
Hopkins University Press, 1996.
10 Andersen TF, Madsen M, Jrgensen J, Mellemkjr L, Olsen
JH. The Danish National Hospital Register. A valuable source
of data for modern health sciences.
Dan Med Bull
1999;
46
:
263268.
11 Nielsen GL, Srensen HT, Larsen H, Pedersen L. Risk of
adverse birth outcome and miscarriage in pregnant users of
non-steroidal anti-inammatory drugs: population based
observational study and casecontrol study.
BMJ
2001;
322
:
266270.
12 Olsen JH, Srensen HT, Friis S
et al.
Cancer risk in users
of calcium channel blockers.
Hypertension
1997;
29
: 1091
1094.
13 Olesen C, Sndergaard C, Thrane N, Nielsen GL, de Jong-
van den Berg L, Olsen J. Do pregnant women report use of
dispensed medications?
Epidemiology
2001;
12
: 497501.
14 Czeizel AE, Intody Z, Modell B. What proportion of
congenital abnormalities can be prevented?
BMJ
1993;
306
:
499503.
15 Mitchell AA. Special considerations in studies of drug-
induced birth defects. In
Pharmacoepidemiology
, 2nd edn, ed.
Strom BL. Chichester: Wiley, 1994: 595607.
Maternal use of amoxicillin and pregnancy outcome
2003 Blackwell Science Ltd
Br J Clin Pharmacol
,
55
, 216221
221
16 Ness RB, Grisso JA, Hirschinger N
et al.
Cocaine and
tobacco use and the risk of spontaneous abortion.
N Engl J
Med
1999;
340
: 333339.
17 Olsen J, Frische G. Social differences in reproductive health.
A study on birth weight, stillbirths and congenital
malformations in Denmark.
Scand J Soc Med
1993; 21: 9097.
18 Rockenbauer M, Olsen J, Czeizel AE, Pedersen L, Srensen
HT. Recall bias in a casecontrol surveillance system on the
use of medicine during pregnancy. Epidemiology 2001; 12:
461466.